- Details
- Description
-
Packaging Size20ml/bottle
-
Strength600mg
-
CompositonSugemalimab
-
TreatmentNon-small cell lung cancer
-
FormInjection
-
BrandCejemly®
-
Quantity Unit600mg(20.0ml)/bottle
-
ManufacturerCStone Pharmaceuticals
Contents
hide
About Cejemly® (Sugemalimab)
The anti-PD-L1 monoclonal antibody sugemalimab was discovered by CStone using the OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.
Approval
The NMPA of China has approved sugemalimab for four indications:
- In combination with chemotherapy for first-line treatment of patients with metastatic squamous and non-squamous NSCLC.
- For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.
- For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma.
- In combination with fluorouracil and platinum-based chemotherapy for first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC.
July 26, 2024 — CStone Announces European Commission (EC) Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC.
- Sugemalimab sold as brand name 择捷美® in china.
- Sugemalimab sold as brand name Cejemly® in European Union.
Reference: 《CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer 》
